These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 32869324)

  • 21. Direct Oral Anticoagulant Adherence of Patients With Atrial Fibrillation Transitioned from Warfarin.
    Pundi KN; Perino AC; Fan J; Schmitt S; Kothari M; Szummer K; Askari M; Heidenreich PA; Turakhia MP
    J Am Heart Assoc; 2021 Dec; 10(23):e020904. PubMed ID: 34779243
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Non-warfarin oral anticoagulant copayments and adherence in atrial fibrillation: A population-based cohort study.
    Rome BN; Gagne JJ; Avorn J; Kesselheim AS
    Am Heart J; 2021 Mar; 233():109-121. PubMed ID: 33358690
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of oral anticoagulation use and adherence among Medicare beneficiaries enrolled in stand-alone prescription drug plans vs Medicare Advantage prescription drug plans.
    Newman TV; Gabriel N; Liang Q; Drake C; El Khoudary SR; Good CB; Gellad WF; Hernandez I
    J Manag Care Spec Pharm; 2022 Feb; 28(2):266-274. PubMed ID: 35098746
    [No Abstract]   [Full Text] [Related]  

  • 24. An early evaluation of bleeding-related hospital readmissions among hospitalized patients with nonvalvular atrial fibrillation treated with direct oral anticoagulants.
    Deitelzweig S; Bruno A; Trocio J; Tate N; Gupta K; Lin J; Lingohr-Smith M
    Curr Med Res Opin; 2016; 32(3):573-82. PubMed ID: 26652179
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of Treatment Persistence with Dabigatran or Rivaroxaban versus Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients: A Competing Risk Analysis in the French National Health Care Databases.
    Maura G; Billionnet C; Alla F; Gagne JJ; Pariente A
    Pharmacotherapy; 2018 Jan; 38(1):6-18. PubMed ID: 29028119
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-world adherence to oral anticoagulants in atrial fibrillation patients: a study protocol for a systematic review and meta-analysis.
    Rodríguez-Bernal CL; García-Sempere A; Hurtado I; Santa-Ana Y; Peiró S; Sanfélix-Gimeno G
    BMJ Open; 2018 Dec; 8(12):e025102. PubMed ID: 30573490
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic Significance of Nuisance Bleeding in Anticoagulated Patients With Atrial Fibrillation.
    O'Brien EC; Holmes DN; Thomas LE; Fonarow GC; Allen LA; Gersh BJ; Kowey PR; Singer DE; Ezekowitz MD; Naccarelli GV; Ansell JE; Chan PS; Mahaffey KW; Go AS; Freeman JV; Reiffel JA; Peterson ED; Piccini JP; Hylek EM
    Circulation; 2018 Aug; 138(9):889-897. PubMed ID: 29678813
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adherence to oral anticoagulants in patients with non-valvular atrial fibrillation: the role of patients' characteristics and out-of-pocket payments.
    Al-Obaidi S; Hijazeen R; Arabyat RM; Alabbadi I
    Expert Rev Pharmacoecon Outcomes Res; 2024 Sep; 24(7):845-852. PubMed ID: 38967473
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical Characteristics, Oral Anticoagulation Patterns, and Outcomes of Medicaid Patients With Atrial Fibrillation: Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF I) Registry.
    O'Brien EC; Kim S; Thomas L; Fonarow GC; Kowey PR; Mahaffey KW; Gersh BJ; Piccini JP; Peterson ED
    J Am Heart Assoc; 2016 May; 5(5):. PubMed ID: 27146448
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Three-month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: The SAMURAI-Nonvalvular Atrial Fibrillation (NVAF) study.
    Arihiro S; Todo K; Koga M; Furui E; Kinoshita N; Kimura K; Yamagami H; Terasaki T; Yoshimura S; Shiokawa Y; Kamiyama K; Takizawa S; Okuda S; Okada Y; Nagakane Y; Kameda T; Hasegawa Y; Shibuya S; Ito Y; Nakashima T; Takamatsu K; Nishiyama K; Matsuki T; Homma K; Takasugi J; Tokunaga K; Sato S; Kario K; Kitazono T; Toyoda K;
    Int J Stroke; 2016 Jul; 11(5):565-74. PubMed ID: 26927811
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcomes of anticoagulant prescribing for older patients with atrial fibrillation depends on disability level provided by long-term care insurance.
    Yamada Y; Kojima T; Umeda-Kameyama Y; Ogawa S; Eto M; Akishita M
    Arch Gerontol Geriatr; 2021; 96():104434. PubMed ID: 34030044
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oral anticoagulant adherence and switching in patients with atrial fibrillation: A prospective observational study.
    Salmasi S; Safari A; Kapanen A; Adelakun A; Kwan L; MacGillivray J; Andrade JG; Deyell MW; Loewen P
    Res Social Adm Pharm; 2022 Nov; 18(11):3920-3928. PubMed ID: 35753963
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Trends in utilization of warfarin and direct oral anticoagulants in older adult patients with atrial fibrillation.
    Alalwan AA; Voils SA; Hartzema AG
    Am J Health Syst Pharm; 2017 Aug; 74(16):1237-1244. PubMed ID: 28652320
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Trends in oral anticoagulant choice for acute stroke patients with nonvalvular atrial fibrillation in Japan: the SAMURAI-NVAF study.
    Toyoda K; Arihiro S; Todo K; Yamagami H; Kimura K; Furui E; Terasaki T; Shiokawa Y; Kamiyama K; Takizawa S; Okuda S; Okada Y; Kameda T; Nagakane Y; Hasegawa Y; Mochizuki H; Ito Y; Nakashima T; Takamatsu K; Nishiyama K; Kario K; Sato S; Koga M;
    Int J Stroke; 2015 Aug; 10(6):836-42. PubMed ID: 25581108
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Medical costs in the US of clinical events associated with oral anticoagulant (OAC) use compared to warfarin among non-valvular atrial fibrillation patients ≥75 and <75 years of age, based on the ARISTOTLE, RE-LY, and ROCKET-AF trials.
    Deitelzweig S; Amin A; Jing Y; Makenbaeva D; Wiederkehr D; Lin J; Graham J
    J Med Econ; 2013 Sep; 16(9):1163-8. PubMed ID: 23869941
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real-World Adherence and Persistence with Direct Oral Anticoagulants in Adults with Atrial Fibrillation.
    Manzoor BS; Lee TA; Sharp LK; Walton SM; Galanter WL; Nutescu EA
    Pharmacotherapy; 2017 Oct; 37(10):1221-1230. PubMed ID: 28730619
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Real-World Clinical Characteristics and Treatment Patterns of Individuals Aged 80 and Older with Nonvalvular Atrial Fibrillation: Results from the ReAl-life Multicenter Survey Evaluating Stroke Study.
    Biteker M; Başaran Ö; Doğan V; Altun İ; Özpamuk Karadeniz F; Tekkesin Aİ; Çakıllı Y; Türkkan C; Hamidi M; Demir V; Gürsoy MO; Tek Öztürk M; Aksan G; Seyis S; Ballı M; Alıcı MH; Bozyel S
    J Am Geriatr Soc; 2017 Aug; 65(8):1684-1690. PubMed ID: 28394435
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Appropriateness of oral anticoagulant therapy prescription and its associated factors in hospitalized older people with atrial fibrillation.
    Franchi C; Antoniazzi S; Proietti M; Nobili A; Mannucci PM;
    Br J Clin Pharmacol; 2018 Sep; 84(9):2010-2019. PubMed ID: 29745441
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Regular Bleeding Risk Assessment Associated with Reduction in Bleeding Outcomes: The mAFA-II Randomized Trial.
    Guo Y; Lane DA; Chen Y; Lip GYH;
    Am J Med; 2020 Oct; 133(10):1195-1202.e2. PubMed ID: 32289310
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Translating claims-based CHA
    Webster-Clark M; Huang TY; Hou L; Toh S
    Pharmacoepidemiol Drug Saf; 2020 Apr; 29(4):409-418. PubMed ID: 32067286
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.